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Abstract
Background: Anthracycline-based treatment remains the backbone of chemotherapy for nonresectable soft tissue
sarcomas (STS). More than 30 % of patients with STS are aged 60 years or older, limiting the choice of treatment to
single-agent approaches for this elderly population. Hematological toxicity is frequent during doxorubicin monotherapy,
grade 4 neutropenia is reported in 34 %, with a febrile neutropenia rate of 9 % in STS. We assume that comorbidities in
the elderly population may limit tolerability of doxorubicin, and novel agents may improve tolerability and health-related
quality of life while maintaining efficacy. We therefore investigated whether the tyrosine kinase inhibitor pazopanib
exerts such a clinical benefit in elderly patients with STS (pazopanib for elderly [the EPAZ study]).
Methods/design: This study is a randomized, controlled, open-label, multicenter, phase II noninferiority trial in which
pazopanib 800 mg once daily is being compared six cycles of intravenous doxorubicin 75 mg/m2 as first-line treatment
in elderly patients (≥60 years) with metastatic or advanced STS. A total of 120 patients will be randomized 1:2 to receive
doxorubicin or pazopanib, stratified by Eastern Cooperative Oncology Group performance status (0–1 vs. 2) and
liposarcoma histology (yes vs. no).
The primary endpoint is progression-free survival based on local tumor assessment according to Response Evaluation
Criteria in Solid Tumors criteria. Secondary endpoints include grade 4 neutropenia and febrile neutropenia in hierarchical
order, as well as overall survival, objective response rate, health-related quality of life, and geriatric assessments.
Discussion: Pazopanib is associated with promising tolerability according to previous studies and may offer a significant
clinical advantage in first-line treatment of STS compared with doxorubicin. The elderly population seems especially
appealing for such an approach, since these patients are not suitable for aggressive combination therapy. The EPAZ
study will confirm whether pazopanib may be an alternative to toxic chemotherapy for elderly patients with STS.
Trial registration: ClinicalTrials.gov NCT01861951; registered on 11 April 2013. EudraCT 2011-004168-30; registered on
4 June 2012.
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Background
Soft tissue sarcomas (STS) are malignant, heterogeneous
tumors that typically arise in the mesodermal tissues of
the extremities (50 %), trunk and retroperitoneum (40 %),
or head and neck (10 %) [1]. Their histology is diverse,
and more than 50 different subtypes are recognized in the
current classification system [2].
STS in adults are rare and have an estimated incidence
of 4–5 per 100,000 per year in Europe [3]. In the United
States, more than 10,000 new cases were reported in
2010 [4]. The aggressiveness of STS is emphasized by
the high death rate, with nearly 4000 deaths occurring in
the United States in 2010. Risk factors for recurrent dis-
ease are described as incomplete resection, high-grade
histology, STS larger than 5 cm, and deep location [5].
As a result of STS heterogeneity, the development of an
effective antitumor agent has been difficult. For decades,
doxorubicin has formed the backbone of systemic treat-
ment of a wide range of cancers, including hematological
malignancies, many types of carcinoma, and unresectable
or metastatic STS [6]. Doxorubicin treatment is frequently
associated with hematological toxicity. Grade 4 neutro-
penia has been reported in 34–37 % of patients with STS
during treatment with doxorubicin, and 9–13 % of all pa-
tients being treated with doxorubicin experience febrile
neutropenia [7, 8].
Elderly patients are known to be prone to comorbidities,
and aggressive treatment may not be feasible for these pa-
tients, which is why multiagent chemotherapy is not rec-
ommended for them. However, grade 4 neutropenia and
neutropenic fever are considered severe side effects of pal-
liative treatment and may be poorly tolerated by elderly
patients. Finding an alternative agent with similar efficacy
but fewer and less severe adverse effects (AEs) is therefore
particularly important for this patient group.
A promising candidate for this purpose could be pazo-
panib, which is an orally administered, potent, multitar-
geted receptor tyrosine kinase inhibitor. Pazopanib has
demonstrated encouraging results in clinical trials in renal
cell carcinoma, ovarian cancer, early-stage non-small cell
lung cancer, breast cancer, and cervical cancer [9–14]. In a
phase II study of patients with advanced or metastatic
STS receiving pazopanib as a second-line therapy, the
progression-free rate (PFR) at 12 weeks was 44 % (18 of
41 subjects) for leiomyosarcoma, 49 % (18 of 37 subjects)
for synovial sarcoma, 26 % (5 of 19) for adipocytic sar-
coma, and 39 % (16 of 41 subjects) for other types of sar-
coma [15]. Agents with a PFR of at least 40 % at 12 weeks
are suggested to show adequate drug activity in pretreated
patients [16]. Therefore, further clinical development of
pazopanib excluded patients with adipocytic sarcoma
from clinical trials after the given phase II results. The
PALETTE (pazopanib for metastatic soft-tissue sarcoma)
study investigators assessed pazopanib in comparison with
placebo in STS excluding adipocytic differentiation [17].
Pazopanib achieved a significant improvement in median
progression-free survival (PFS) from 1.6 to 4.6 months
(p < 0.0001), which was the primary endpoint of the trial.
Overall survival increased from 10.7 to 12.5 months (HR
0.86, 95 % CI 0.7–1.1; p = 0.25), but the study size was too
small to detect such a treatment effect.
Overall, pazopanib offers a distinct mechanism of ac-
tion and spectrum of adverse events, thereby offering
some advantage over conventional chemotherapy. In our
present study, we are testing this hypothesis in compari-




The primary aim of this study is to show that PFS in the
pazopanib group is not inferior to PFS in the doxorubicin
group. Key secondary objectives are to show superiority of
pazopanib compared with doxorubicin regarding neutro-
penia grade 4 and/or febrile neutropenia. Further second-
ary objectives are to analyze treatment effects on overall
survival, objective tumor response, time to onset of re-
sponse, quality of life, safety, and tolerability, as well as to
investigate predictive biomarkers.
Study design
This trial is a randomized, open-label, multicenter, phase
II noninferiority study designed to compare pazopanib
with doxorubicin as first-line treatment in elderly patients
with metastatic or advanced STS. A total of 120 patients
from 13 (German and Belgian) study centers will be en-
rolled, comprising 40 patients in the doxorubicin arm and
80 patients who will receive pazopanib.
The overall study duration will be approximately
50 months, including a recruitment period of 36 months, a
4.5-month period of treatment with doxorubicin (18 weeks)
or pazopanib until treatment failure, and follow-up of at
least 10 months.
Baseline and follow-up assessments are performed ac-
cording to a predefined schedule (see Fig. 1 and Additional
file 1: Figure S1). Follow-up visits occur at the same time
points for both treatment arms. In both treatment groups,
an end-of-treatment visit 4 weeks after the end of treatment
is performed. Tumor images obtained by performing
computed tomography or magnetic resonance imaging
for evaluation of response and progress are taken every
6–7 weeks in the first 6 months and every 12 weeks
after week 26 until progression. The Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
checklist and assessment figure of the trial can be found in
Additional file 2: Table S1 and Additional file 1: Figure S1.
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Ethical considerations
The trial protocol was approved by the ethics committee
of Hannover Medical School and the ethics committees
of all participating study centers (see Additional file 3).
The study is registered at ClinicalTrials.gov (identifier
NCT01861951) and ClinicalTrialsRegister.eu (identifier
2011-004168-30). The results of the trial will be reported
in accordance with the Consolidated Standards of
Reporting Trials (CONSORT) statement [18, 19].
Study population
Male and female patients with metastatic or advanced
STS who are at least 60 years of age are screened for the
study. After they provide signed written informed con-
sent, their eligibility is determined on the basis of the in-
clusion and exclusion criteria listed in Table 1.
Randomization and blinding
This is an open-label study with a 1:2 randomization ratio
for doxorubicin/pazopanib. Blinding was considered to be
ethically infeasible due to the different dosing schedules
and routes of administration. A fax randomization is
centrally performed at the Institute for Biostatistics in
Hannover according to a permuted block randomization
list with varying block sizes. Randomization is stratified
for Eastern Cooperative Oncology Group (ECOG) per-
formance status (0–1 vs. 2) and liposarcoma histology (yes
vs. no) at randomization.
Interventions
Control intervention
Doxorubicin is an anthracycline antibiotic with a mechan-
ism of action aimed at topoisomerase inhibition. Doxo-
rubicin (monotherapy) is administered intravenously every
3 weeks at a dose of 75 mg/m2 body surface area for a
total of six cycles.
Experimental intervention
Pazopanib is a once-daily, orally administered angiogen-
esis inhibitor targeting vascular endothelial growth factor
(VEGF), platelet-derived growth factor, and c-kit receptors
[20]. By inhibiting these receptors, pazopanib may stop or
slow the rate of tumor growth and development. Pazopa-
nib is provided as white tablets with two doses at 200 mg
and 400 mg. Patients receive a daily dose of 800 mg.
Treatment is administered until disease progression, treat-
ment failure, or death due to any cause, whichever occurs
first. Pazopanib has been approved by the U.S. Food and
Drug Administration, the European Medicines Agency,
and other regulatory authorities as a monotherapy for pa-
tients with advanced renal cell carcinoma and as second-
line therapy for advanced STS.
Dose adjustments
Dose reduction, delay of administration, and treatment
interruption might become necessary for reasons of tox-
icity in both treatment groups. Patients with dose adjust-
ments are closely monitored (weekly). Dose modification
algorithms are given in the study protocol. As a general
rule, pazopanib is reduced stepwise each 10–14 days in
200-mg decrements. If the toxicity has abated with dose
reduction and dose re-escalation is considered safe by the
investigator, the pazopanib dose is increased stepwise back
to the pre-event dose. For doxorubicin, a 1-week treat-
ment delay and/or a 20 % dose reduction (i.e., 60 mg/m2)
are suggested. Dose modifications to 60 mg/m2 doxorubi-
cin are allowed once and cannot be re-escalated. If toxicity
does not abate during the monitoring period, administra-
tion of pazopanib or doxorubicin is interrupted and/or the
dose is further reduced. It should be permanently discon-
tinued for any hematological or nonhematological toxicity
requiring an interruption of ≥14 days.
Fig. 1 Schedule of visits and treatment. RECIST Response Evaluation Criteria in Solid Tumors
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Outcomes
Primary endpoint
The primary endpoint is PFS, calculated as time from
the date of randomization until the date of first objective
documentation of disease progression, treatment failure,
or death due to any cause, whichever occurs first.
Secondary endpoints
Key secondary outcomes are the rates of grade 4 neutro-
penia and of febrile neutropenia. Rates are defined as the
number of scheduled examinations where grade 4 neu-
tropenia is diagnosed (febrile neutropenia respectively)
divided by the follow-up time until progression, death,
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Signed written informed consent • STS of uncertain differentiation (epithelioid, alveolar soft part, clear cell,
desmoplastic small round cell, malignant mesenchymoma, PEComa),
chondrosarcoma, Ewing sarcoma/PNET, chordoma, malignant solitary fibrous
tumors, embryonal rhabdomyosarcoma, osteosarcoma, gastrointestinal stromal
tumors, dermatofibrosarcoma protuberans, inflammatory myofibroblastic
sarcoma (low grade), neuroblastoma, malignant mesothelioma, mixed
mesodermal tumors of the uterus
• Age ≥60 years • Prior malignancy, except for subjects who have been disease-free for 2 years,
or complete resection of nonmelanomatous skin carcinoma, or successfully
treated in situ carcinoma or incidental prostate cancer (TNM stage T1a or T1b)
• ECOG performance status of 0–2 • History or clinical evidence of CNS metastases; previously treated subjects
without signs of activity are allowed
• Histologically confirmed diagnosis of metastatic or advanced
STS of intermediate or high grade
• Clinically significant gastrointestinal abnormalities that may increase the risk
for gastrointestinal bleeding or may affect absorption of IMP
• Evidence of progressive disease within 6 months prior to
study inclusion
• Presence of uncontrolled infection
• Availability of archived tumor tissue of the most recent histology • QTc >480 milliseconds using Bazett’s formula
• Adequate organ system function as determined by
laboratory assessment
• History of any of the following cardiovascular conditions within the past
6 months: cardiac angioplasty or stenting, myocardial infarction, unstable
angina, coronary artery bypass graft surgery, symptomatic peripheral vascular
disease, cerebrovascular accident (including TIA), pulmonary embolism, or
untreated deep vein thrombosis
• Adequate contraception for patients or partners with
childbearing potential
• Class III or IV congestive heart failure as defined by the NYHA classification system
• Negative pregnancy test for women of childbearing potential • Poorly controlled hypertension
• Major surgery or trauma within 28 days before first dose of IMP and/or presence
of any nonhealing wound, fracture, or ulcer
• Evidence of active bleeding or bleeding diathesis
• Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels
• Hemoptysis in excess of 2.5 ml once within 8 weeks of first dose of IMP
• Any serious and/or unstable preexisting medical, psychiatric, or other condition
that could interfere with subject’s safety, provision of informed consent, or
compliance with study procedures
• Unable or unwilling to discontinue use of prohibited medications for at least 14 days or
5 half-lives of a drug (whichever is longer) prior to the first dose of IMP and for the
duration of the study
• Treatment with any anticancer therapies
• Any ongoing toxicity from prior anticancer therapy that is higher than CTCAE
grade 1 and/or that is progressing in severity, except alopecia
• Prior systemic therapy for metastatic or advanced disease; neoadjuvant or
adjuvant chemotherapy is allowed, unless disease progression occurred within
6 months following end of treatment
• Participation in any other clinical trial within 30 days before the study begins
• Known hypersensitivity to any component of IMPs
Abbreviations: CTCAE Common Terminology Criteria for Adverse Events, ECOG Eastern Cooperative Oncology Group, IMP investigational medical product, NYHA
New York Heart Association, PEComa perivascular epithelioid cell tumor, PNET primitive neuroectodermal tumor, QTc corrected QT interval, STS soft tissue
sarcomas, TIA transient ischemic attack
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or the end of the study, or (in case of treatment switch)
until initiation of another anticancer treatment. Incident
diagnoses will be considered at the next examination. In
addition to the primary outcome, PFRs after 12 and
26 weeks from the date of randomization and overall
survival, defined as time from randomization to death
due to any cause, will be estimated. Further secondary
endpoints are objective tumor response, calculated as
objective response rate, along with time to onset of re-
sponse. Assessment of response and progression is based
on Response Evaluation Criteria in Solid Tumors version
1.1, without independent review of tumor response or
progression events.
Safety and tolerability will be assessed continuously
throughout the course of the study. Toxic and side effects
are evaluated by using the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events version 4.0.
Quality of life is measured with the European Organisa-
tion for Research and Treatment of Cancer (EORTC)
30-item core quality of life questionnaire (the QLQ-
C30). Geriatric assessments are made according to the
EORTC Elderly Task Force guidelines.
The predictive role of biomarkers will be assessed to
predict the PFS rate at 26 weeks after the start of treat-
ment. Biomarkers measured in the study will include
placental growth factor, fibroblast growth factor, VEGF,
PDGF, angiopoietin 2, and interleukin 8. Blood samples
will be taken at baseline, at 2 weeks, and at each scheduled
follow-up visit starting from 3 weeks after randomization.
Further assessments
A large panel of clinical and laboratory data is being col-
lected in the trial. At each visit, a physical examination
is conducted, including assessment of vital signs, and
information on hematology and clinical chemistry is ob-
tained, which are particularly important for assessment
of tolerability. Evaluation furthermore comprises liver
function tests, coagulation tests, proteinuria via urinaly-
sis, thyroid function tests, and lipid tests. Echocardiog-
raphy is performed at baseline and at week 26. Based on
the key secondary endpoints, primary and secondary
prophylaxis of neutropenia assessment is of key import-
ance. Primary and secondary prophylaxis of neutropenia
are routinely assessed and documented for each cycle.
The participating trial centers have decided at baseline
whether they will implement primary prophylaxis.
Sample size considerations
Sample size is feasibility-driven because of orphan drug
conditions [21], and, in consequence, our power calcula-
tion describes under which circumstances this trial can
reach an adequate power for an achievable sample size. In
this study a maximum of 120 patients can be included
within a reasonable time frame of 3 years of recruitment.
With a 1:2 randomization, this leads to 40 patients in the
doxorubicin arm and 80 patients in the pazopanib arm.
The one-sided type I error rate is set to 2.5 %. The treat-
ment groups will be compared by using HRs. For both
treatment groups, a median PFS of 6 months is assumed
[8, 22]. The accrual time is 36 months, and the minimum
observational time is 10 months. Under these conditions,
noninferiority with a margin of 1.8 for the HR can be con-
cluded with a power of >80 %. An anticipated rate of
dropout and exclusion from the primary analysis popula-
tion of 10 % maintains a power of 79–80 %.
Statistical analysis
Primary analysis
The primary analysis will be performed on the per-
protocol (PP) population and, as a sensitivity analysis, on
the intention-to-treat (ITT) population. Consistency be-
tween results in ITT and PP analysis is needed to draw
any conclusion regarding differences in PFS. The PP
population will include all randomized patients who re-
ceived the assigned study treatment and took the study
medication according to the protocol (allowing for dose
reduction and/or temporary interruption, or termination
of trial drug intake without other anticancer therapy be-
ing initiated before documented progression). If patients
start another anticancer therapy, they will be censored at
the respective time point in the ITT analysis.
For PFS, a Cox regression model will be used to calcu-
late the HR of pazopanib/doxorubicin and the respective
two-sided 95 % CI. If the upper limit of this CI in the PP
population is less than 1.8, noninferiority will be con-
cluded. The Cox regression model is adjusted for ECOG
score (0–1 vs. 2) and liposarcoma histology (yes vs. no).
Kaplan-Meier curves will be drawn.
Secondary and safety analyses
If statistical significance is reached for the primary end-
point, a confirmatory analysis of the key secondary end-
points grade 4 neutropenia and febrile neutropenia will
be performed in hierarchical order. If no statistically sig-
nificant difference for grade 4 neutropenia is observed,
febrile neutropenia will be considered descriptively. The
rates of grade 4 neutropenia will be analyzed with a
Poisson regression model adjusted for ECOG score and
liposarcoma histology and allowing for clustering of the
outcome within patients by using a random effects term.
Superiority of pazopanib will be concluded if the upper
boundary of the two-sided 95 % CI for the rate ratio
(pazopanib/doxorubicin) is below 1. Rates of febrile neu-
tropenia will be analyzed with the same approach. Due
to the hierarchical order in confirmatory testing, no ad-
justment for multiplicity has to be done.
For the analysis of overall survival, Kaplan-Meier curves
and Cox regression will be used. For analysis of PFRs after
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12 and 26 weeks, a logistic regression model will be used
to calculate the OR between the two treatment groups.
Corresponding two-sided 95 % CIs will be calculated. The
objective tumor response rate will be computed with 95 %
CIs in each treatment arm. Patients with progression, early
death, or unknown status are considered as failures. Time
to onset of response will be reported as median and range.
Occurrence and frequency of AEs and serious AEs will be
evaluated separately for both treatment groups, and fre-
quency tables and corresponding 95 % CIs will be shown.
The key secondary analyses and analyses of all further
efficacy endpoints will be conducted on the ITT popula-
tion with sensitivity analyses based on the PP popula-
tion. Analysis of safety endpoints will be conducted on
the full analysis set. No interim analyses are planned in
this trial.
Discussion
Pazopanib has been approved as a monotherapy treatment
for patients with advanced renal cell carcinoma and as
second-line therapy for advanced STS. On the basis of
current clinical data suggesting a favorable safety profile of
pazopanib, it is justifiable to develop pazopanib for use as
first-line treatment for STS. The elderly population seems
especially appealing for such an approach, since these pa-
tients generally are not suitable for aggressive combination
therapy, and thus pazopanib could be an alternative to
toxic chemotherapy. For this target population, the EPAZ
trial (A Trial Comparing Two Medications as First Treat-
ment in Elderly Patients with Metastatic or Advanced Soft
Tissue Sarcoma) will provide important insights on the ef-
ficacy and safety of pazopanib compared with the current
standard treatment with doxorubicin.
The design and performance of a randomized con-
trolled trial in elderly patients with STS are hampered
by the facts that STS is a rare disease with orphan status
[21] and only a small number of patients are available
for study enrollment. According to the respective guide-
lines [23, 24], clinical trials in small populations ought to
be planned with the best, most suitable study design to
produce unbiased and interpretable study results. Hence,
a randomized, multicenter, active control, noninferiority
trial design with PFS as a valid primary surrogate end-
point has been chosen.
We extensively discussed the noninferiority margin
prior to the study. A margin of 1.8 for the HR of disease
progression appears to be quite high compared with non-
inferiority margins of other cancer studies (HR 1.2–1.5).
The chosen margin of HR of 1.8 corresponds to a possible
decrease in PFS from 6 months to 3.3 months, which,
from a clinical point of view, is relevant and unacceptable.
However, in view of the small achievable sample size, the
study will inevitably generate large CIs for the HR and will
therefore be severely underpowered when using the usual
“resolution.” There are different strategies to handle this
problem: (1) increase the significance level to obtain tiny
CIs or (2) relax the noninferiority margin, or (3) change
nothing and be prepared to obtain nonsignificant (but
clinically interpretable) results. We decided to customize
the noninferiority margin to a level at which the study has
appropriate power to be formally successful if both treat-
ments have at least the same PFS (HR ≤1). We should
keep in mind that the power diminishes rapidly if the true
HR is only slightly greater than 1 (i.e., in favor of doxo-
rubicin). In this study setting of rare patients and very
wide CIs, a strong focus can be put only on the observed
point estimates and their clinical interpretation. Decisions
regarding application of the proposed treatment strategy
or further clinical studies will not be based solely on the
significance or nonsignificance of a defined primary end-
point, but they will be made taking into account all rele-
vant aspects in the entire trial dataset. This means that all
benefits and risks observed in the EPAZ trial will be dis-
cussed in detail and will form the basis of an overall clin-
ical conclusion.
We included assessment of key secondary endpoints that
are clinically relevant. Neutropenia and febrile neutropenia
are believed to have high impact in the elderly population.
Therefore, both factors were considered relevant in the
context of the noninferiority design with broad margins.
Nevertheless, observed point estimates and confidence
limits of PFS rates and of the respective HR (pazopanib/
doxorubicin) will particularly be assessed for clinically rele-
vant differences and will be carefully discussed when inter-
preting the results.
Randomization and analysis are stratified for two import-
ant prognostic factors: ECOG performance status and lipo-
sarcoma histology. It can be assumed that the power is
increased by performing stratified analyses [23]. Nonethe-
less, a limitation of the EPAZ study design is the low power
for drawing an overall positive conclusion. Obviously, the
aim of the study is to show comparable efficacy accompan-
ied by considerable advantages in terms of safety issues
and increased health-related quality of life (HRQoL) as a
consequence. However, the study is powered only for the
primary objective, because the orphan conditions do not
allow us to adequately power the study for the primary as
well as the two key secondary endpoints, or even additional
secondary objectives. We expect that, on basis of the safety
profile of either drug and the continuous evaluation of
HRQoL, we will be able to show a clinically meaningful
benefit of the given therapy. To our understanding, EPAZ
is the first study in STS that weights the quality of PFS and
will provide data regarding comorbidities and HRQoL in
the elderly population.
Pazopanib is an effective treatment in STS. Its activity in
previously treated patients is within the range of contem-
porary first-line activity of doxorubicin [8, 17]. However,
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the classes of agents used differ substantially between
pazopanib and doxorubicin. While pazopanib is an oral
tyrosine kinase inhibitor that inhibits the VEGFR, doxo-
rubicin is a classical chemotherapeutic compound. Hence,
its toxicity profile differs substantially. It is not known
how continuous exposure with chronic toxicity affects pa-
tients in comparison with chemotherapy, with its cyclic
treatment and adverse events. The principal applicability
to elderly patients has been shown in metastatic renal can-
cer, a disease whose incidence peaks in the sixth and sev-
enth decades of life [25]. If both noninferiority in efficacy
and an improved tolerability of pazopanib (and thus im-
proved quality of life) are verified in our trial, a new first-
line treatment strategy for elderly patients with STS may
become available.
Trial status
This trial was initiated in October 2012. Recruitment
was completed in March 2016, and follow-up is ongoing.
Additional files
Additional file 1: Figure S1. SPIRIT schedule of enrollment,
assessments, and interventions in the EPAZ study. (DOC 96 kb)
Additional file 2: Table S1. SPIRIT 2013 Checklist: Recommended items
to address in a clinical trial protocol and related documents. (PDF 1880 kb)
Additional file 3: List of all ethical bodies that approved the EPAZ
study. (DOCX 14 kb)
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